BioPharma Dive October 17, 2025
Regeneron Pharmaceuticals, Revolution Medicines and Disc Medicine were among the first beneficiaries of a pilot program the FDA announced in June.
A gene therapy for hearing loss, an experimental pancreatic cancer treatment and seven other medications have been chosen as the first recipients of a new voucher the Food and Drug Administration is using to dramatically speed up drug reviews.
In a statement Thursday, the agency said that these nine treatments — medicines from Regeneron Pharmaceuticals, Revolution Medicines and Disc Medicine, among others — were awarded what’s been called a “national priority voucher.” These vouchers are part of a pilot program announced in June and can shorten a drug’s FDA evaluation to as little as one to two months....
Today's Sponsors
Today's Sponsor